KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP trimmed its holdings in KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) by 7.7% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 534,979 shares of the specialty pharmaceutical company’s stock after selling 44,680 shares during the period. Dimensional Fund Advisors LP owned 1.27% of KalVista Pharmaceuticals worth $6,303,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in KALV. nVerses Capital LLC purchased a new position in KalVista Pharmaceuticals during the second quarter worth $25,000. EntryPoint Capital LLC bought a new position in shares of KalVista Pharmaceuticals during the first quarter worth about $92,000. China Universal Asset Management Co. Ltd. raised its stake in KalVista Pharmaceuticals by 101.6% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 8,024 shares of the specialty pharmaceutical company’s stock valued at $95,000 after acquiring an additional 4,043 shares in the last quarter. Entropy Technologies LP acquired a new stake in shares of KalVista Pharmaceuticals in the 1st quarter worth approximately $121,000. Finally, PEAK6 Investments LLC acquired a new position in KalVista Pharmaceuticals during the first quarter worth about $178,000.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a report on Monday, September 9th. Needham & Company LLC restated a “buy” rating and issued a $32.00 price objective on shares of KalVista Pharmaceuticals in a research note on Friday, September 6th. Finally, HC Wainwright reiterated a “buy” rating and set a $20.00 price target on shares of KalVista Pharmaceuticals in a report on Monday.

Insiders Place Their Bets

In other news, CEO Benjamin L. Palleiko sold 14,215 shares of the company’s stock in a transaction that occurred on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the sale, the chief executive officer now owns 242,527 shares in the company, valued at $2,912,749.27. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. In other KalVista Pharmaceuticals news, insider Christopher Yea sold 7,102 shares of the stock in a transaction on Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $85,295.02. Following the transaction, the insider now owns 84,467 shares in the company, valued at $1,014,448.67. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Benjamin L. Palleiko sold 14,215 shares of the firm’s stock in a transaction dated Monday, August 19th. The stock was sold at an average price of $12.01, for a total transaction of $170,722.15. Following the transaction, the chief executive officer now directly owns 242,527 shares in the company, valued at approximately $2,912,749.27. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,804 shares of company stock valued at $372,112 in the last three months. 12.30% of the stock is currently owned by corporate insiders.

KalVista Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ KALV opened at $11.21 on Wednesday. KalVista Pharmaceuticals, Inc. has a 12-month low of $7.21 and a 12-month high of $16.88. The company has a market cap of $472.93 million, a price-to-earnings ratio of -3.30 and a beta of 0.89. The firm’s 50-day simple moving average is $12.01 and its 200 day simple moving average is $12.07.

KalVista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Thursday, September 5th. The specialty pharmaceutical company reported ($0.87) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.91) by $0.04. On average, equities analysts expect that KalVista Pharmaceuticals, Inc. will post -3.35 earnings per share for the current year.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.